Literature DB >> 26991617

Distinct Hypnotic Recoveries After Infusions of Methoxycarbonyl Etomidate and Cyclopropyl Methoxycarbonyl Metomidate: The Role of the Metabolite.

Ervin Pejo1, Jifeng Liu, Xiangjie Lin, Douglas E Raines.   

Abstract

BACKGROUND: Methoxycarbonyl etomidate (MOC-etomidate) and cyclopropyl methoxycarbonyl metomidate (CPMM) are rapidly metabolized "soft" etomidate analogs. CPMM's duration of hypnotic effect is context insensitive, whereas MOC-etomidate's is not. In this study, we tested the hypothesis that CPMM's effect is context insensitive because, unlike MOC-etomidate, its metabolite fails to reach physiologically important concentrations in vivo even with prolonged continuous infusion.
METHODS: We compared the potencies with which MOC-etomidate and CPMM activate α1(L264T)β3γ2 γ-aminobutyric acid type A receptors and induce loss-of-righting reflexes (i.e., produce hypnosis) in tadpoles with those of their metabolites (MOC-etomidate's carboxylic acid metabolite [MOC-ECA] and CPMM's carboxylic acid metabolite [CPMM-CA], respectively). We measured metabolite concentrations in the blood and cerebrospinal fluid of Sprague-Dawley rats on CPMM infusion and compared them with those achieved with MOC-etomidate infusion. We measured the rates with which brain tissue from Sprague-Dawley rats metabolize MOC-etomidate and CPMM.
RESULTS: Both analogs and their metabolites enhanced γ-aminobutyric acid type A receptor function and induced loss-of-righting reflexes in a concentration-dependent manner. However, in these 2 assays, CPMM-CA's potency relative to its parent hypnotic was approximately 1:4900 and 1:1900, respectively, whereas MOC-ECA's was only approximately 1:415 and 1:390, respectively. With 2-hour CPMM infusions, CPMM-CA reached respective concentrations in the blood and cerebrospinal fluid that were 2 and >3 orders of magnitude lower than that which produced hypnosis. CPMM was metabolized by the brain tissue at a rate that is approximately 1/15th that of MOC-etomidate.
CONCLUSIONS: Hypnotic recovery after CPMM administration is context insensitive because its metabolite does not accumulate to hypnotic levels in the central nervous system. This reflects the very large potency ratio between CPMM and CPMM-CA and the resistance of CPMM to metabolism by esterases present in the brain.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26991617      PMCID: PMC4800831          DOI: 10.1213/ANE.0000000000001146

Source DB:  PubMed          Journal:  Anesth Analg        ISSN: 0003-2999            Impact factor:   5.108


  25 in total

Review 1.  Recent advances in retrometabolic drug design and targeting approaches.

Authors:  N Bodor
Journal:  Pharmazie       Date:  2000-03       Impact factor: 1.267

Review 2.  Structure-based estimation of enzymatic hydrolysis rates and its application in computer-aided retrometabolic drug design.

Authors:  P Buchwald; N Bodor
Journal:  Pharmazie       Date:  2000-03       Impact factor: 1.267

Review 3.  Physicochemical aspects of the enzymatic hydrolysis of carboxylic esters.

Authors:  P Buchwald; N Bodor
Journal:  Pharmazie       Date:  2002-02       Impact factor: 1.267

Review 4.  Structure-metabolism relationships: steric effects and the enzymatic hydrolysis of carboxylic esters.

Authors:  P Buchwald
Journal:  Mini Rev Med Chem       Date:  2001-05       Impact factor: 3.862

Review 5.  Saturable pharmacokinetics in the renal excretion of drugs.

Authors:  C A van Ginneken; F G Russel
Journal:  Clin Pharmacokinet       Date:  1989-01       Impact factor: 6.447

6.  Pharmacokinetics of esmolol and ASL-8123 in renal failure.

Authors:  J F Flaherty; B Wong; G La Follette; D G Warnock; J D Hulse; J G Gambertoglio
Journal:  Clin Pharmacol Ther       Date:  1989-03       Impact factor: 6.875

7.  Remifentanil: a unique opioid analgesic.

Authors:  C Rosow
Journal:  Anesthesiology       Date:  1993-11       Impact factor: 7.892

8.  Kinetics of esmolol, an ultra-short-acting beta blocker, and of its major metabolite.

Authors:  C Y Sum; A Yacobi; R Kartzinel; H Stampfli; C S Davis; C M Lai
Journal:  Clin Pharmacol Ther       Date:  1983-10       Impact factor: 6.875

9.  Gating allosterism at a single class of etomidate sites on alpha1beta2gamma2L GABA A receptors accounts for both direct activation and agonist modulation.

Authors:  Dirk Rüsch; Huijun Zhong; Stuart A Forman
Journal:  J Biol Chem       Date:  2004-03-11       Impact factor: 5.157

10.  Preliminary pharmacokinetics and pharmacodynamics of an ultra-short-acting opioid: remifentanil (GI87084B).

Authors:  P S Glass; D Hardman; Y Kamiyama; T J Quill; G Marton; K H Donn; C M Grosse; D Hermann
Journal:  Anesth Analg       Date:  1993-11       Impact factor: 5.108

View more
  5 in total

Review 1.  The Role of GABA Receptor Agonists in Anesthesia and Sedation.

Authors:  Janette Brohan; Basavana G Goudra
Journal:  CNS Drugs       Date:  2017-10       Impact factor: 5.749

Review 2.  Structural Modification in Anesthetic Drug Development for Prodrugs and Soft Drugs.

Authors:  Chaoyi Deng; Jin Liu; Wensheng Zhang
Journal:  Front Pharmacol       Date:  2022-07-01       Impact factor: 5.988

3.  Sedative-hypnotic Binding to 11β-hydroxylase.

Authors:  Ervin Pejo; Xiaojuan Zhou; S Shaukat Husain; Douglas E Raines
Journal:  Anesthesiology       Date:  2016-11       Impact factor: 7.892

Review 4.  GABAA receptors as targets for anaesthetics and analgesics and promising candidates to help treat coronavirus infections: A mini-review.

Authors:  Yujia Luo; Thomas Balle
Journal:  Basic Clin Pharmacol Toxicol       Date:  2022-09-27       Impact factor: 3.688

Review 5.  Recent advances in intravenous anesthesia and anesthetics.

Authors:  Mohamed Mahmoud; Keira P Mason
Journal:  F1000Res       Date:  2018-04-17
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.